ImmunityBio Stock Surges 15% on ANKTIVA’s 700% Revenue Growth
ImmunityBio, Inc. (IBRX) shares rallied 15.73% to $10.81 following explosive 2025 earnings showing ANKTIVA's net product revenue soaring 700%. The immunotherapy specialist reported $113 million in annual revenue, with Q4 alone delivering a 20% sequential jump. Unit sales of its flagship cancer treatment skyrocketed 750% year-over-year.
Global expansion accelerated with regulatory approvals now spanning 33 countries—including the US, EU, UK, and Saudi Arabia. The Saudi clearance notably expands ANKTIVA's addressable market into lung cancer, with commercial launch expected within 60 days. ImmunityBio's cash position of $242.8 million and patent protection extending beyond 2035 provide runway for its expanding clinical pipeline.